亚洲成色在线综合网站免费丨a 成 人小说网站在线观看丨自拍偷自拍亚洲精品10p丨色综合av亚洲超碰少妇丨午夜观看福利一区

Many industrial innovative products are coming soon

COVID-19 antibody detection reagent and many other products go out of China and enter the international market

Expanded R&D team and introduced new R&D technology

Realized whole-line cold chain logistics for the first time nationwide

Completed the development and started the clinical test of many industry-leading project, such as irradiator, multiple, HIV, etc.

Be recognized as provincial level innovation and industrialization demonstration enterprise for several times

Established "Guangdong Postdoctoral Innovation Practice Base"

Be approved as a national “Post-Doctoral Research Center”

Established Suzhou R&D center

Moved into the new industrial park with a floor area of 23,000 m2

Cooperated with many international IVD enterprises, such as Unipath, Fujirebro, Siemens, MP, etc.

The market share of AIDS confirmation reagents reached 80%, and the market share of drug concentration detection reached 50%,Many self-developed products occupied over 60% of the market share.Many products became reference methods for disease detection, such as MYCOII and TP.PA.

1989, the first subsidiary of Livzon Pharmaceutical Group Inc.

Obtained pharmaceutical manufacturing license

Many products were successfully developed and marketed, including HBV, HIV, HCV ELISA reagents